Products

ABMD Software
HeartLung Corporation
Endocrinology & Metabolic AI
ABMD Software by HeartLung Corporation is an AI-powered, cloud-based tool for opportunistic osteoporosis screening, assessing bone mineral density from existing CT scans without additional radiation.
AI-CVD
HeartLung Corporation
Cardiology AI
AI-CVD® is an FDA-cleared, AI-powered quantitative imaging platform from HeartLung Corporation that performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks.

See all 2 products →

About HeartLung

HeartLung Technologies is a healthcare AI company dedicated to advancing AI-enabled, CT-based opportunistic screening and early disease detection. The company’s mission is to shift healthcare from late-stage disease treatment to earlier identification and prevention by leveraging artificial intelligence to unlock clinically actionable information embedded within routine medical imaging.

For physicians, HeartLung offers a suite of AI-powered quantitative imaging platforms, including AI-CVD®, AI-CAC™, AutoChamber™, and AutoBMD™. These solutions are designed to extract preventive insights from existing chest and abdominal CT scans without requiring additional imaging, radiation, contrast, or workflow disruption. For instance, AutoChamber™ is an FDA-designated Breakthrough AI that opportunistically flags enlarged heart chambers on non-contrast CT scans, which may be invisible to the human eye, helping to identify patients at risk of heart failure, atrial fibrillation, and stroke.

HeartLung’s technologies enable the automated detection and quantification of various conditions, including coronary heart disease, heart failure, atrial fibrillation, stroke, osteoporosis, liver steatosis, diabetes, lung cancer, emphysema/COPD, and myosteatosis. The company’s AI-CAC™ (Agatston 2.0) improves upon traditional coronary artery calcium scoring by detecting even small, diffuse, or semi-calcified plaques, enhancing cardiovascular risk prediction. HeartLung’s AutoBMD™ provides DEXA-equivalent, CT-based opportunistic osteoporosis screening.

Focus Areas

early detection of heart disease lung cancer osteoporosis fatty liver disease emphysema/COPD myosteatosis cardiovascular disease stroke atrial fibrillation heart failure

Business Intelligence

PartnershipsSimonMed Imaging, Capitol Imaging Services, 3DR Labs, Microsoft for Healthcare (Precision Imaging Network)
TechnologyAI-powered quantitative imaging platform, deep learning, cloud-based SaaS, opportunistic screening from routine CT scans, PACS integration
FDA Clearances3 cleared products (estimated)

What Physicians Need to Know

Comprehensive Early Detection
HeartLung specializes in the early detection of a broad spectrum of critical conditions including heart disease, lung cancer, osteoporosis, fatty liver disease, emphysema/COPD, myosteatosis, cardiovascular disease, stroke, atrial fibrillation, and heart failure.
Multi-Organ System Focus
Unlike single-disease screening tools, HeartLung offers a holistic approach by simultaneously assessing risks across cardiovascular, pulmonary, metabolic, and musculoskeletal systems.
Proactive Health Management
By identifying diseases at their earliest stages, HeartLung empowers physicians to intervene proactively, potentially preventing disease progression and improving long-term patient outcomes.
Advanced Risk Stratification
The platform provides sophisticated risk stratification, allowing physicians to identify high-risk patients who would benefit most from targeted interventions and lifestyle modifications.
Physician Tip

HeartLung's platform is designed to seamlessly integrate into your practice, offering actionable insights for patient management. Utilize our comprehensive reports to guide preventative care discussions, inform specialist referrals, and monitor disease progression. The multi-disease screening capability allows for a more efficient and thorough assessment during routine check-ups, helping you identify silent diseases before they become symptomatic. Focus on the early identification of at-risk patients to implement timely interventions, improve patient adherence to treatment plans, and ultimately enhance overall patient quality of life.

HeartLung is built with interoperability in mind, offering robust API capabilities for seamless integration with existing Electronic Health Record (EHR) and Picture Archiving and Communication System (PACS) systems. This ensures a streamlined workflow, reducing administrative burden and allowing physicians to access critical patient data directly within their preferred clinical environment.

Products by HeartLung

2 products in the directory

ABMD Software
HeartLung Corporation
Endocrinology & Metabolic AI
ABMD Software by HeartLung Corporation is an AI-powered, cloud-based tool for opportunistic osteoporosis screening, assessing bone mineral density from existing CT scans without additional radiation.
AI-CVD
HeartLung Corporation
Cardiology AI
AI-CVD® is an FDA-cleared, AI-powered quantitative imaging platform from HeartLung Corporation that performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks.

Reviews & Opinions

No web reviews on file yet for HeartLung. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about HeartLung.

Loading videos...

Videos load interactively. If none appear, search YouTube for HeartLung →

View all on YouTube

Press & Coverage

PRWeb
FDA Clears HeartLung's AI-CVDu00ae, Enabling the Broadest Opportunistic Cardiovascular & Multisystem CT Screening Platform
HeartLung Corporation announced U.S. FDA clearance of AI-CVDu00ae, its AI-powered quantitative imaging platform, which enables automated extraction of cardiovascular and systemic measurements from existing CT scans for opportunistic screening across ten indications.
2026-01
DAIC
HeartLung.AI Tool Receives 'FDA Breakthrough' AI Clearance
HeartLung Technologies' AI-enabled Automated Cardiac Chambers Volumetry (AutoChamber) received FDA Breakthrough Medical Device designation and marketing authorization for early detection of heart disease on non-contrast CT scans.
2024-10
EIN Presswire (via The National Law Review)
HeartLung AI Welcomes CMS Coverage for AI-Enabled Opportunistic Coronary Artery Calcium (CAC) Detection on Chest CT
HeartLung AI welcomed CMS's establishment of HCPCS code G0680, effective April 1, 2026, creating a reimbursement pathway for AI-enabled opportunistic cardiovascular assessment from routine chest CT in the hospital outpatient setting.
2026-04
The National Law Review
HeartLung Announces USPTO Issuance of Foundational AI-CVD Patent and Allowance for Vasa Vasorum Inflammation Imaging
HeartLung Corporation announced that the USPTO has issued a foundational patent for its AI-CVD platform and allowed a patent for vasa vasorum inflammation imaging, strengthening its intellectual property in AI-enabled preventive CT imaging.
2026-05
EIN Presswire
Study Shows AI-CVDu00ae Outperforms Diabetes in Predicting Heart Failure Risk
HeartLung Corporation published a new study in the American Journal of Preventive Cardiology demonstrating that its AI-CVD AutoChamber module can identify heart failure risk from routine coronary artery calcium scans, outperforming diabetes as a predictor.
2026-05
FirstWord HealthTech
HeartLung Technologies Sets New Milestone with Nine Accepted Abstracts at AHA 2025 Showcasing the Power of AI-CVDu2122
HeartLung Technologies announced a record-setting presence at the American Heart Association (AHA) Scientific Sessions 2025, with nine peer-reviewed studies accepted for presentation, highlighting breakthroughs from its AI-CVDu2122 platform.
2025-10
The National Law Review
HeartLung Launches 'Why Pay More and Get Less?' Campaign at SCCT 2026
HeartLung Corporation launched its 'Why Pay More and Get Less?' campaign at SCCT 2026, contrasting coronary plaque-centric AI-CCTA marketing with AI-CVD's CAC-based, whole-patient primary prevention approach.
2026-07
EIN Presswire (via The National Law Review)
Two HeartLung.AI Studies Show Routine Chest CT Assesses Cardiac Risk Like Dedicated Cardiac CT and Echocardiography
HeartLung.AI announced the acceptance of two studies in the American Journal of Preventive Cardiology, demonstrating that AI can extract clinically meaningful cardiac chamber measurements from routine non-gated, non-contrast chest CT.
2026-07

Frequently Asked Questions

HeartLung specializes in AI-powered imaging analysis and biomarker assays designed for the early detection of a broad spectrum of conditions. Our product suite includes solutions for identifying subtle indicators of lung cancer, cardiovascular disease, osteoporosis, and metabolic disorders like fatty liver disease, often leveraging existing imaging data.
Our technologies undergo rigorous clinical validation through multi-center studies and peer-reviewed publications, demonstrating high sensitivity and specificity in identifying early disease markers. We focus on evidence-based outcomes that show improved patient stratification and timely intervention, leading to better prognoses.
HeartLung prioritizes seamless integration with major EHR platforms through standard APIs and customizable interfaces to minimize disruption to clinical workflows. Our goal is to provide actionable insights directly within the physician's existing system, enhancing decision-making without adding significant administrative burden.
HeartLung's diagnostic tools hold relevant regulatory clearances, such as FDA 510(k) for applicable devices, and we are committed to achieving further certifications as our product line expands. We adhere strictly to HIPAA and other global data privacy regulations, employing robust encryption and de-identification protocols to safeguard patient information.
Our pricing model is typically subscription-based, offering tiered options depending on the scale of implementation and specific modules utilized, designed to be predictable and scalable. Healthcare organizations often see ROI through earlier disease detection leading to reduced downstream treatment costs, improved patient outcomes, and enhanced preventative care initiatives.
HeartLung provides comprehensive onboarding, including on-site and virtual training sessions for clinical and IT staff, tailored to specific roles and workflows. Our dedicated support team offers 24/7 technical assistance and clinical guidance, ensuring continuous optimal performance and user proficiency.
HeartLung is backed by strong venture capital funding and strategic partnerships, providing a solid financial foundation for sustained growth and innovation. Our long-term vision is to be the leading partner in preventative health, continuously expanding our diagnostic capabilities and global reach to empower earlier interventions and improve population health.

Related Companies

QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]

Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.